© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Sarclisa

FDA Approves New Sarclisa Regimen for Multiple Myeloma

The monoclonal antibody reduces the risk of disease progression or death by 45%.

Sarclisa

FDA Approves Sarclisa for People With Previously Treated Multiple Myeloma

Approval was based on a study showing combination treatment reduced disease progression or death by 40%.
Advertisement

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.